Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
CLDN7 Antibody (C-term)
Affinity Purified Rabbit Polyclonal Antibody (Pab)
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application 
| FC, IHC-P, WB, E |
|---|---|
| Primary Accession | O95471 |
| Other Accession | NP_001171951.1, NP_001298.3 |
| Reactivity | Human |
| Host | Rabbit |
| Clonality | Polyclonal |
| Isotype | Rabbit IgG |
| Calculated MW | 22418 Da |
| Antigen Region | 172-201 aa |
| Gene ID | 1366 |
|---|---|
| Other Names | Claudin-7, CLDN-7, CLDN7, CEPTRL2, CPETRL2 |
| Target/Specificity | This CLDN7 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 172-201 amino acids from the C-terminal region of human CLDN7. |
| Dilution | WB~~1:1000 IHC-P~~1:50~100 FC~~1:10~50 |
| Format | Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification. |
| Storage | Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. |
| Precautions | CLDN7 Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures. |
| Name | CLDN7 |
|---|---|
| Synonyms | CEPTRL2, CPETRL2 |
| Function | Plays a major role in tight junction-specific obliteration of the intercellular space. |
| Cellular Location | Cell membrane; Multi-pass membrane protein. Basolateral cell membrane. Cell junction, tight junction. Note=Co-localizes with EPCAM at the basolateral cell membrane and tight junction |
| Tissue Location | Expressed in kidney, lung and prostate. Isoform 1 seems to be predominant, except in some normal prostate samples, where isoform 2 is the major form. Down-regulated in breast cancers, including ductal carcinoma in situ (DCIS), lobular carcinoma in situ (LCIS) and invasive ductal carcinoma (IDC) (at protein level), as well as in several cancer cell lines. Loss of expression correlates with histological grade, occurring predominantly in high-grade lesions |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
This gene encodes a member of the claudin family. Claudins are integral membrane proteins and components of tight junction strands. Tight junction strands serve as a physical barrier to prevent solutes and water from passing freely through the paracellular space between epithelial or endothelial cell sheets, and also play critical roles in maintaining cell polarity and signal transductions. Differential expression of this gene has been observed in different types of malignancies, including breast cancer, ovarian cancer, hepatocellular carcinomas, urinary tumors, prostate cancer, lung cancer, head and neck cancers, thyroid carcinomas, etc.. Alternatively spliced transcript variants encoding different isoforms have been found.
References
Kojima, F., et al. Oncol. Rep. 23(4):927-931(2010)
Rendon-Huerta, E., et al. J Gastrointest Cancer 41(1):52-59(2010)
Ouban, A., et al. Histol. Histopathol. 25(1):83-90(2010)
Kaarteenaho, R., et al. Respir. Res. 11, 59 (2010) :
Lal-Nag, M., et al. Genome Biol. 10 (8), 235 (2009) :
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Other Products
Shipping Information
